ENSURE phase III trial
The superior efficacy of erlotinib over chemotherapy as first-line treatment for EGFR Mut+ NSCLC, observed in the OPTIMAL study, was confirmed in this broader Asian population. Erlotinib’s favourable safety profile was also confirmed.1
Patients who received erlotinib had significantly longer PFS than patients receiving chemotherapy.
Patients treated with erlotinib experienced fewer treatment-related severe AEs, fewer Grade ≥3 AEs and fewer dose modifications due to AEs, than patients treated with chemotherapy.
Please click here for further safety data